5174 Predictive factors of response to neoadjuvant 3-weekly epirubicin (EPI) plus docetaxel (DOC) chemotherapy (CT) in locally advanced breast cancer (LABC): a prospective phase II trial
EJC SUPPLEMENTS(2009)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要